RLYB supply chain intelligence for Rallybio Corporation: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Rallybio Corporation (RLYB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AVENZO | AVENZO | 90% | a termination fee of $600,000 may be payable by Rallybio to Avenzo if (i)(a) the Merger Agreement is terminated because the Merger has not been consummated by the End Date |
| CANDID | CANDID | 90% | On March 1, 2026, Rallybio entered into an Agreement and Plan of Merger and Reorganization with Candid pursuant to which the parties intended to undertake a business combination. |
| CANDID-THERAPEUTICS-INC | CANDID-THERAPEUTICS-INC | 90% | Candid and UCB, on behalf of themselves and their respective affiliates, agreed to release Parent and its affiliates from all claims in respect of the Merger Agreement, the Contemplated Transactions … |
| SANOFI | SANOFI | 90% | We paid Sanofi an upfront cash payment of $3.0 million. |
| UCB-S-A | UCB-S-A | 90% | Candid and UCB, on behalf of themselves and their respective affiliates, agreed to release Parent and its affiliates from all claims in respect of the Merger Agreement, the Contemplated Transactions … |
| SOBI | SOBI | 85% | we entered into an agreement with Sobi, pursuant to which we acquired the right, title and interest in assets related to certain C5 inhibitor compounds. |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from RLYB graph: any sublicenses) will terminate and (b) if Sanofi has an interest in developing, manufacturing and commercializing the… |
| JNJ | Johnson & Johnson | 72% | any sublicenses) will terminate and (b) if Sanofi has an interest in developing, manufacturing and commercializing the licensed compounds or products, the parties to the Sanofi License Agreement shal… |
| SNYNF | Sanofi | 72% | any sublicenses) will terminate and (b) if Sanofi has an interest in developing, manufacturing and commercializing the licensed compounds or products, the parties to the Sanofi License Agreement shal… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from RLYB graph: any sublicenses) will terminate and (b) if Sanofi has an interest in developing, manufacturing and commercializing t… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| JJDC | JJDC | 92% | The Company recognized revenue of $ 0.2 million for both the three months ended March 31, 2026 and 2025, related to data collection and data submission with the identified performance obligations, an… |
| AVENZO | AVENZO | 85% | Pursuant to the Subscription Agreement, and subject to the terms and conditions therein, Avenzo agreed to sell, and the Investors agreed to purchase, immediately prior to the Effective Time, shares o… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from RLYB graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from RLYB graph: any sublicenses) will terminate and (… |
| JNJ | Johnson & Johnson | 72% | any sublicenses) will terminate and (b) if Sanofi has an interest in developing, manufacturing and commercializing the licensed compounds or products, the parties to the Sanofi License Agreement shal… |
| SNYNF | Sanofi | 72% | ompany determined that the J&J Collaboration Agreement is not in the scope of ASC 808. Asset Acquisition In May 2022, we obtained worldwide exclusive rights to RLYB331, with Kymab Limited ("Sanofi") … |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from RLYB graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from RLYB graph: ompany determined that the J&J Co… |
| ABCELLERA-BIOLOGICS-INC | ABCELLERA-BIOLOGICS-INC | 62% | iance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration combined AbCellera Biologics Inc.'s ("AbCellera's") anti… |
| COMPANY-LLC | COMPANY-LLC | 62% | s; ▪ costs related to manufacturing material for our clinical trials, including expenses related to the manufacturing scale-up and fees paid to contract manufacturing organizations ("CMOs"); 89 T a b… |
| COORDINATION-GROUP | COORDINATION-GROUP | 62% | sublicenses) will terminate and (b) if Sanofi has an interest in developing, manufacturing and commercializing the licensed compounds or products, the parties to the Sanofi License Agreement shall ne… |
| EMERGING-GROWTH-COMPANY | EMERGING-GROWTH-COMPANY | 62% | ay 2026, we received a $50.0 million Parent Termination Fee in connection with the termination of the Merger Agreement. As of March 31, 2026, we had $46.8 million of cash, cash equivalents and market… |
| KYMAB-LIMITED | KYMAB-LIMITED | 62% | ASC 808, Collaborative Arrangements . F-15 T a b le of Contents Asset Acquisition In May 2022, we obtained worldwide exclusive rights to RLYB331, with Kymab Limited ("Sanofi") a preclinical antibody.… |
| MOMENTA-PHARMACEUTICALS-INC | MOMENTA-PHARMACEUTICALS-INC | 62% | sublicenses) will terminate and (b) if Sanofi has an interest in developing, manufacturing and commercializing the licensed compounds or products, the parties to the Sanofi License Agreement shall ne… |
| NASDAQ-STOCK-MARKET-LLC | NASDAQ-STOCK-MARKET-LLC | 62% | . Solely for convenience, trademarks and trade names referred to in this Annual Report on Form 10-K, including logos, artwork and other visual displays, may appear without the ® or TM symbols, but su… |
| RECURSION-EXSCIENTIA-VENTURES-I-INC | RECURSION-EXSCIENTIA-VENTURES-I-INC | 62% | sublicenses) will terminate and (b) if Sanofi has an interest in developing, manufacturing and commercializing the licensed compounds or products, the parties to the Sanofi License Agreement shall ne… |
| USA-LLC | USA-LLC | 62% | ices; 23 Table of Contents ▪ costs related to manufacturing material for our clinical trials, including expenses related to the manufacturing scale-up and fees paid to contract manufacturing organiza… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| RLYB-DEBT | Debt stack $154,000 | 90% | Market cache reports total debt of $154,000. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| RLYB-OWNER-JOHNSON-JOHNSON | JOHNSON & JOHNSON | 90% | 13F overlay lists JOHNSON & JOHNSON as top holder; 3 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| CSTE | Caesarstone Ltd. | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 |